News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Treatment-experienced people news

Show

From To
New and experimental HIV treatments
What Lies Ahead: An Activist's View of Promising HIV Treatment Research

After attending the 18th Conference on Retroviruses and Opportunistic Infections (CROI 2011) in Boston, Mass., and following different areas of research, I decided to write down a list of advancements that really thrill and energize me as an educator and research advocate.

Published
31 March 2011
From
The Body
Treatment-experienced people
Zambia: 'Only Four Percent Need Third Line ARV Treatment'

Only four per cent of patients on ARVs need second or third line treatment, the Ministry of Health has said.

Published
15 March 2011
From
AllAfrica
Treatment-experienced people
ZAMBIA: Third-line ARVs available soon

After months of lobbying and campaigning by Zambian activists, the government has announced that it will provide free third-line antiretroviral (ARV) drugs to people living with HIV.

Published
08 March 2011
From
IRIN Plus News
Clinical trials
AIDS Activists Call on Public to Support New FDA HIV Drug Approval Policy

The AIDS Treatment Activists Coalition (ATAC) is asking people to sign on to a letter in support of a proposed U.S. Food and Drug Administration (FDA) policy that will hopefully make it easier for drugs to be approved for heavily treatment experienced people.

Published
23 February 2011
From
Poz
Treatment-experienced people
New Possibility for Some Heavily Treatment Experienced: Add Reyataz or Invirase

A drug-resistance mutation in HIV’s protease gene may actually be advantageous and make the virus more sensitive to antiretroviral drug regimens containing either Reyataz (atazanavir) or Invirase (saquinavir), according to a paper published online ahead of print in AIDS Research and Therapy.

Published
22 February 2011
From
AIDSMeds
Resistance
Little evidence of transmission of virus that's resistant to newer anti-HIV drugs

Italian investigators have found evidence of the transmission of HIV that is resistant to the fusion inhibitor T-20 (enfuvirtide, Fuzeon). However, there is at yet no evidence

Published
09 February 2011
By
Michael Carter
Treatment-experienced people
Drug Resistance Shouldn’t Preclude Using NRTIs in an HIV Salvage Regimen

People with heavily drug-resistant HIV benefit from adding two nucleoside reverse transcriptase inhibitors (NRTIs) to a regimen that contains Isentress (raltegravir), even if their virus is partially or fully resistant to the NRTIs. These data were published online January 28 in the Journal of Acquired Immune Deficiency Syndromes.

Published
02 February 2011
From
AIDSMeds
Treatment-experienced people
Darunavir once-daily approved in Europe for treatment-experienced

The European Medicines Agency has approved once-daily dosing of the HIV protease inhibitor darunavir (Prezista) for treatment-experienced adults without signs of potential resistance to the drug. Once-daily dosing of

Published
24 January 2011
By
Keith Alcorn
Treatment-experienced people
Manufacturer Recalls Alcohol Swab Products Packaged with Fuzeon, Other Meds

The Triad Group alcohol prep pads, which may be contaminated with Bacillus cereus are co-packaged and distributed with some medications used by people living with HIV, including Genentech's Fuzeon (enfuvirtide) and Pegasys (pegylated interferon, used to treat chronic hepatitis C virus infection).

Published
20 January 2011
From
AIDSmeds
Treatment-experienced people
Once-daily darunavir approved for some treatment-experienced patients in US

The United States Food and Drug Administration has approved new dosing for the protease inhibitor darunavir (Prezista) that will allow the drug to be dosed once daily for

Published
14 December 2010
By
Keith Alcorn
← Prev12345...13Next →

Filter by country